US 12,268,732 B2
IL-15-based molecules with anti-CD20 antibody and methods of use
Bai Liu, Culver City, CA (US); Peter Rhode, Culver City, CA (US); Wenxin Xu, Culver City, CA (US); and Hing C. Wong, Culver City, CA (US)
Assigned to Altor Bioscience, LLC., Culver City, CA (US)
Filed by Altor Bioscience, LLC, Culver City, CA (US)
Filed on Jun. 7, 2024, as Appl. No. 18/737,455.
Application 18/737,455 is a division of application No. 18/639,659, filed on Apr. 18, 2024.
Application 18/639,659 is a division of application No. 18/394,409, filed on Dec. 22, 2023, granted, now 12,097,244.
Application 18/063,871 is a division of application No. 17/825,959, filed on May 26, 2022, granted, now 11,679,144, issued on Jun. 20, 2023.
Application 15/921,512 is a division of application No. 14/755,989, filed on Jun. 30, 2015, granted, now 9,925,247, issued on Mar. 27, 2018.
Application 18/394,409 is a continuation of application No. 18/063,871, filed on Dec. 9, 2022, granted, now 11,890,323, issued on Feb. 6, 2024.
Application 17/825,959 is a continuation of application No. 16/925,138, filed on Jul. 9, 2020, granted, now 11,471,511, issued on Oct. 18, 2022.
Application 16/925,138 is a continuation of application No. 16/444,807, filed on Jun. 18, 2019, granted, now 11,173,191, issued on Nov. 16, 2021.
Application 16/444,807 is a continuation of application No. 15/921,512, filed on Mar. 14, 2018, granted, now 10,537,615, issued on Jan. 21, 2020.
Claims priority of provisional application 62/018,899, filed on Jun. 30, 2014.
Prior Publication US 2024/0307494 A1, Sep. 19, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/20 (2006.01); A61K 38/17 (2006.01); A61K 39/395 (2006.01); A61K 47/64 (2017.01); A61P 35/00 (2006.01); A61K 39/04 (2006.01); C07K 14/35 (2006.01); C07K 14/54 (2006.01); C07K 14/715 (2006.01); C07K 16/28 (2006.01)
CPC A61K 38/2086 (2013.01) [A61K 38/1793 (2013.01); A61K 39/39558 (2013.01); A61K 47/6425 (2017.08); A61P 35/00 (2018.01); A61K 39/04 (2013.01); C07K 14/35 (2013.01); C07K 14/5443 (2013.01); C07K 14/7155 (2013.01); C07K 16/2818 (2013.01); C07K 16/2827 (2013.01); C07K 16/2887 (2013.01); C07K 16/2896 (2013.01); C07K 2317/732 (2013.01); C07K 2319/30 (2013.01); C07K 2319/32 (2013.01)] 5 Claims
OG exemplary drawing
 
1. A method for treating a neoplasia in a human subject, the method comprising: administering to said subject an effective amount of an isolated anti-CD20 antibody comprising an Fc domain capable of mediating antibody-dependent cell cytotoxicity, and wherein the method further comprises administering by subcutaneous administration to said subject an effective amount of a pharmaceutical composition comprising an IL-15N72D:IL-15RαSu/Fc complex comprising an IL-15N72D having the amino acid sequence of SEQ ID NO: 3 and an IL-15RαSu/Fc fusion protein having the amino acid sequence of SEQ NO: 6, wherein the IL-15N72D:IL-15RαSu/Fc complex comprises a dimeric IL-15RaSu/Fc and two IL-15N72D molecules, and wherein the effective amount of the IL-15N72D:IL-15RαSu/Fc complex is between 0.1 μg/kg and 100 mg/kg, thereby treating the neoplasia.